Elanco Animal Health (NYSE:ELAN) Releases Q3 2025 Earnings Guidance

Key Points

• Elanco Animal Health has issued a third quarter 2025 earnings guidance with an EPS range of 0.120-0.160, aligning closely with the consensus estimate of 0.134. The company also forecasts revenues of $1.1 billion.
• The company updated its full-year 2025 EPS guidance to a range of 0.850-0.910, reflecting optimism despite a year-over-year revenue decline of 1% in a prior quarter.
• Analysts remain bullish on Elanco, with several upgrading their price targets to an average of $16.17, indicating confidence in the stock's performance.

Elanco Animal Health (NYSE:ELAN - Get Free Report) updated its third quarter 2025 earnings guidance on Thursday. The company provided earnings per share guidance of 0.120-0.160 for the period, compared to the consensus earnings per share estimate of 0.134. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion. Elanco Animal Health also updated its FY 2025 guidance to 0.850-0.91 EPS.

Elanco Animal Health Price Performance

Elanco Animal Health stock traded up $0.33 on Monday, reaching $17.00. The company's stock had a trading volume of 4,226,663 shares, compared to its average volume of 5,408,638. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.40 and a current ratio of 2.60. Elanco Animal Health has a twelve month low of $8.02 and a twelve month high of $17.29. The company has a market cap of $8.45 billion, a price-to-earnings ratio of 19.78, a PEG ratio of 3.12 and a beta of 1.66. The business's fifty day moving average price is $14.32 and its 200 day moving average price is $12.08.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported $0.26 EPS for the quarter, beating the consensus estimate of $0.20 by $0.06. Elanco Animal Health had a return on equity of 7.04% and a net margin of 9.68%. The firm had revenue of $1.24 billion during the quarter, compared to analysts' expectations of $1.19 billion. During the same period in the prior year, the firm posted $0.30 earnings per share. The business's quarterly revenue was up 4.8% compared to the same quarter last year. Equities analysts expect that Elanco Animal Health will post 0.91 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on ELAN. Leerink Partnrs raised Elanco Animal Health from a "hold" rating to a "strong-buy" rating in a report on Thursday, July 17th. Piper Sandler boosted their target price on Elanco Animal Health from $12.00 to $18.00 and gave the company a "neutral" rating in a research report on Monday. Leerink Partners raised Elanco Animal Health from a "market perform" rating to an "outperform" rating and set a $18.00 price objective for the company in a report on Thursday, July 17th. William Blair raised Elanco Animal Health from a "market perform" rating to an "outperform" rating in a report on Thursday, June 26th. Finally, Wall Street Zen raised Elanco Animal Health from a "hold" rating to a "buy" rating in a report on Saturday, July 5th. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $17.33.

Institutional Investors Weigh In On Elanco Animal Health

Several institutional investors have recently made changes to their positions in the stock. Goldman Sachs Group Inc. raised its position in shares of Elanco Animal Health by 104.5% in the first quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company's stock worth $50,268,000 after buying an additional 2,445,872 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Elanco Animal Health by 4.5% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,793,337 shares of the company's stock valued at $18,830,000 after acquiring an additional 76,408 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in Elanco Animal Health during the 1st quarter valued at approximately $2,065,000. Finally, Empowered Funds LLC boosted its position in Elanco Animal Health by 35.2% during the 1st quarter. Empowered Funds LLC now owns 15,835 shares of the company's stock valued at $166,000 after acquiring an additional 4,121 shares in the last quarter. Hedge funds and other institutional investors own 97.48% of the company's stock.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.